Associated Papers
The Prevalence and Clinical Characteristics of MYO3A-Associated Hearing Loss in 15,684 Hearing Loss Patients.
Maekawa K et al.
Genes, 2025
Molecular insights into MYO3A kinase domain variants explain variability in both severity and progression of DFNB30 hearing impairment.
Souissi A et al.
Journal of Biomolecular Structure & Dynamics, 2022
A novel missense variant in MYO3A is associated with autosomal dominant high-frequency hearing loss in a German family.
Doll J et al.
Molecular Genetics & Genomic Medicine, 2020
Myosins and Disease.
Coluccio LM
Advances in Experimental Medicine and Biology, 2020
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
Goh G et al.
Plos Medicine, 2016
27923043 (PubMed )
Supplement: pmed.1002136.s018.xlsx › S6_Table
Expanding preconception carrier screening for the Jewish population using high throughput microfluidics technology and next generation sequencing.
Gal M et al.
Bmc Medical Genomics, 2016
27175728 (PubMed )
Supplement: 12920_2016_184_MOESM1_ESM.xls › S1
A mouse model for human hearing loss DFNB30 due to loss of function of myosin IIIA.
Walsh VL et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society, 2011
Deafness genes in Israel: implications for diagnostics in the clinic.
Brownstein Z et al.
Pediatric Research, 2009
From flies' eyes to our ears: mutations in a human class III myosin cause progressive nonsyndromic hearing loss DFNB30.
Walsh T et al.
Proceedings of the National Academy of Sciences of the United States of America, 2002
Select a paper to view details